The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Unexpected Low Efficacy of Caelyx and Vinorelbine in Metastatic Breast Cancer (MBC).
 
Beilei Cai
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Research Funding - Novartis
Travel, Accommodations, Expenses - Novartis
 
Michael Broder
Research Funding - Amgen (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Cholangiocarcinoma Foundation; Eisai; Genentech; Ipsen; Kite, a Gilead company; Novartis; Onconova Therapeutics; Otsuka; Proacta; Sage Therapeutics
 
Eunice Chang
Employment - Partnership for Health Analytic Research
 
Jessie Tingjian Yan
Employment - Partnership for Health Analytic Research
Other Relationship - Tingjian Yan is an employee of Partnership for Health Analytic Research, LLC, a health services research company paid by Novartis to conduct this research.
 
Al Bowen Benson
Consulting or Advisory Role - Advanced Accelerator Applications; Alchemia; Astellas Pharma; Bayer; Bayer/Onyx; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Celgene; DAVA Pharmaceuticals; EMD Serono; Genentech/Roche; Guardant Health; Guerbet; Helsinn Healthcare; Infinity Pharmaceuticals; IntegraGen; Lexicon; Lilly; Lilly/ImClone; Merck Serono; Novartis; Opsona Therapeutics; Pharmacyclics; Precision Therapeutics; Sanofi; Spectrum Pharmaceuticals; Taiho Pharmaceutical; TRM Oncology; Vicus Therapeutics
Research Funding - advanced accelerator applications (Inst); Alchemia (Inst); Amgen (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer/Onyx (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AVEO; Bayer; Boehringer Ingelheim; Boston Biomedical; Dava Oncology; Genentech/Roche; Gilead Sciences; Guardant Health; guerbet; Helsinn Healthcare; Lilly/ImClone; Sanofi; Spectrum Pharmaceuticals; TRM Oncology